2021 American Transplant Congress
An Unusual Viral Tropism in a Solid Organ Transplant Recipient
*Purpose: Cytomegalovirus (CMV) tissue-invasive disease occurs in higher proportion in CMV-mismatched kidney transplant recipients (KTxR) with no pre-existing immunity and those who are markedly immunologically-impaired.…2021 American Transplant Congress
Ganciclovir Therapeutic Drug Monitoring in Obese Adults Patients – Opportunity for Clinical Utility
*Purpose: Ganciclovir (GCV) is the drug of choice for the treatment of cytomegalovirus (CMV) infection; optimal dosing of GCV in the obese patient population is…2021 American Transplant Congress
Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid Organ Transplant Recipients; Single Center Experience
*Purpose: The main objective of the study is to compare the efficacy of the different Valganciclovir dosing strategies in pediatric solid organ transplant recipients with…2020 American Transplant Congress
Evaluation of an Intervention to Reduce Underdosing of Valganciclovir for Primary Prophylaxis of Cytomegalovirus Infection in Donor Seropositive/Recipient Seronegative Kidney and Liver Transplant Recipients
*Purpose: Valganciclovir (VCV) prophylaxis is used to prevent primary cytomegalovirus (CMV) infection in CMV donor seropositive/recipient seronegative (D+/R-) solid organ transplant recipients (SOT). We examined…2020 American Transplant Congress
Valganciclovir Prophylaxis is Not Associated with Polyomavirus Viremia after Renal Transplantation
1Albany Medical Center, Albany, NY, 2Surgery, Albany Medical Center, Albany, NY
*Purpose: Recent studies have implicated prophylactic valganciclovir (VGC) therapy after renal transplantation to be associated with an increased rate of BK polyomavirus viremia and nephropathy.…2019 American Transplant Congress
Ganciclovir Based Prophylaxis against Cytomegalovirus Viremia in Pediatric Renal Transplant Patients: A Systematic Review and Meta-Analysis
*Purpose: Cytomegalovirus (CMV) disease continues to stand as a significant threat to the longevity of renal transplants in children. More pediatric recipients are CMV negative…2019 American Transplant Congress
Lower Rates of Epstein-Barr Virus Viremia and Post-Transplant Lymphoproliferative Disease in Pediatric Solid Organ Transplant Recipients Who Received Valganciclovir Prophylaxis
*Purpose: Antiviral prophylaxis to prevent post-transplant lymphoproliferative disease (PTLD) remains controversial, but some data suggest that valganciclovir or ganciclovir use in Epstein-Barr virus (EBV) high-risk…2019 American Transplant Congress
Letermovir For The Treatment And Secondary Prophylaxis Of Drug Resistant CMV In Solid Organ Transplant Recipients
*Purpose: Although only approved for primary prophylaxis of CMV among allogeneic stem cell transplant recipients, there is great interest in the use of letermovir (LET)…2019 American Transplant Congress
De-Novo Letermovir Resistant Mutations in Cytomegalovirus-Infected Tissues of Solid Organs Transplant Recipients
*Purpose: Letermovir, cytomegalovirus (CMV) DNA-terminase complex (UL51, UL56, and UL89) inhibitor, revealed the efficient prophylactic effect against CMV infection including disease and DNAemia with low-grade…2019 American Transplant Congress
Real World Data Support International Consenus Guidelines on Management of CMV after Kidney Transplantation
Oslo University Hospital - Rikshospitalet, Oslo, Norway
*Purpose: Cytomegalovirus (CMV) naïve kidney transplant recipients (R-) transplanted with an organ from a CMV positive donor (D+) are at high risk for CMV disease.…
American Transplant Congress abstracts